reference/19379828

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19379828

Outgoing Links

Predicate	Object
contentType	Journal Article\|Multicenter Study\|Randomized Controlled Trial
endingPage	1568
issn	0149-2918
issueIdentifier	10
pageRange	1556-1568
publicationName	Clinical Therapeutics
startingPage	1556
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_f3adb2487eb1d8d5b24b68a3e156f5fb
bibliographicCitation	Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006 Oct;28(10):1556–68. doi: 10.1016/j.clinthera.2006.10.007. PMID: 17157112.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c266dadcc4952b62913766c138c1e43f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3e154c2ec730538bcde7f82e39cd259b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_59f472db0bb92472f9822abcb926e1d8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3d6cf87b150f2fe4459c7945506ab096 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d833b7be9a95b195cc2f9001d1f516b5
date	200610
identifier	https://doi.org/10.1016/j.clinthera.2006.10.007 https://pubmed.ncbi.nlm.nih.gov/17157112
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2822 https://portal.issn.org/resource/ISSN/0149-2918
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
discusses	http://id.nlm.nih.gov/mesh/M0016932 http://id.nlm.nih.gov/mesh/M0498840 http://id.nlm.nih.gov/mesh/M0017845 http://id.nlm.nih.gov/mesh/M0010903 http://id.nlm.nih.gov/mesh/M0508515 http://id.nlm.nih.gov/mesh/M0021911 http://id.nlm.nih.gov/mesh/M0018225
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D014230Q000627 http://id.nlm.nih.gov/mesh/D003924Q000188 http://id.nlm.nih.gov/mesh/D011480Q000627 http://id.nlm.nih.gov/mesh/D007004Q000627 http://id.nlm.nih.gov/mesh/D011719Q000627 http://id.nlm.nih.gov/mesh/D054873
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D011480Q000008 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000068900 http://id.nlm.nih.gov/mesh/D007004Q000008 http://id.nlm.nih.gov/mesh/D014230Q000009 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D004359 http://id.nlm.nih.gov/mesh/D014230Q000008 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D010919 http://id.nlm.nih.gov/mesh/D011719Q000008 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D011480Q000009 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D011719Q000009 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D016896
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_55029e08d2afcf59a719caf55a149021 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4091 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7444 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8121 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8179 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_cdf1e220d89c2dcd2e000c3d105bf93e http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4369359 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_3389c62ce3a8d167b2a3c05ee87c671a http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7440 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fa5fc799a3f3c6277beeb3473c262800 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4829 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5793

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129621433 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128240590 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID249070700 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129765044

Total number of triples: 69.